DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

por Luo, Na, Nixon, Mellissa J., Gonzalez-Ericsson, Paula I., Sanchez, Violeta, Opalenik, Susan R., Li, Huili, Zahnow, Cynthia A., Nickels, Michael L., Liu, Fei, Tantawy, Mohammed N., Sanders, Melinda E., Manning, H. Charles, Balko, Justin M.
Publicado 2018

Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer

por Hanna, Ann, Nixon, Mellissa J., Estrada, M. Valeria, Sanchez, Violeta, Sheng, Quanhu, Opalenik, Susan R., Toren, Abigail L., Bauer, Joshua, Owens, Phillip, Mason, Frank M., Cook, Rebecca S., Sanders, Melinda E., Arteaga, Carlos L., Balko, Justin M.
Publicado 2022

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

por Nixon, Mellissa J., Formisano, Luigi, Mayer, Ingrid A., Estrada, M. Valeria, González-Ericsson, Paula I., Isakoff, Steven J., Forero-Torres, Andrés, Won, Helen, Sanders, Melinda E., Solit, David B., Berger, Michael F., Cantley, Lewis C., Winer, Eric P., Arteaga, Carlos L., Balko, Justin M.
Publicado 2019

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

por Formisano, Luigi, Lu, Yao, Servetto, Alberto, Hanker, Ariella B., Jansen, Valerie M., Bauer, Joshua A., Sudhan, Dhivya R., Guerrero-Zotano, Angel L., Croessmann, Sarah, Guo, Yan, Ericsson, Paula Gonzalez, Lee, Kyung-min, Nixon, Mellissa J., Schwarz, Luis J., Sanders, Melinda E., Dugger, Teresa C., Cruz, Marcelo Rocha, Behdad, Amir, Cristofanilli, Massimo, Bardia, Aditya, O’Shaughnessy, Joyce, Nagy, Rebecca J., Lanman, Richard B., Solovieff, Nadia, He, Wei, Miller, Michelle, Su, Fei, Shyr, Yu, Mayer, Ingrid A., Balko, Justin M., Arteaga, Carlos L.
Publicado 2019